Long-term therapeutic effect of pioglitazone on chronic kidney disease (CKD)

Long-term therapeutic effect of pioglitazone on chronic kidney disease (CKD) - Long-term treatment of CKD by pioglitazone.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004071

Enrollment

Registered

2010-08-20

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease (CKD)

Interventions

Patients of intervention group are treated with pioglitazone orally from the dose of 15mg/day, increasecd to the continuous dose of 15-45mg/day within one month, and continued for 3 years. The efficac

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-diabetic chronic kidney disease with proteinuria of 0.3g/day (1+ by test tape) or more.

Exclusion criteria

Exclusion criteria: 1. Chronic renal failure with serum creatinine level above 3.0 mg/dl. 2. Severe liver dysfunction. 3. Severe edema or chronic heart failure. 4. Past history of allergy against pioglitazone. 5. Pregnant or breast feeding patients. 6. Patients with ongoing steroid therapy.

Design outcomes

Primary

Measure	Time frame
Inhibition of deterioration in renal function (serum creatinine, estimated GFR)	—

Secondary

Measure	Time frame
Decrease in levels of proteinuria	—

Countries

Japan

Contacts

Public ContactTakashi Oda

National Defense Medical College Department of Nephrology

takashio@ndmc.ac.jp04-2995-1609

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026